Methods:
This experiment is divided into two phases. Phase I studies the effects of variable fibrinogen concentrations on the degradation properties of fibrin glue in order to identify a polymer that degrades at a rate which is favorable for neocartilage formation.
Phase II studies the optimal chondrocyte concentration necessary to create quality, homogeneous neocartilage using the fibrin glue polymer specified in phase I. All studies were approved by the institutional animal ues committee (IACUC).
Phase I Fibrin glue degradation as a function of fibrinogen concentration
This portion of the study examined the effect of varying concentrations of fibrinogen, as well as a fibronolysis inhibitor (aprotinin) on the degradation of fibrin glue. Fibrin glue was produced by mixing purified porcine fibrinogen (Sigma Corp., St. Louis, MO) with an equal volume of thrombin (GenTrac Inc., St. Louis, Mo ) (50 units per cc in 40 mM calcium chloride). Four mixtures of fibrin glue were created, each with a variable fibrinogen component. The groups had final fibrinogen concentrations of 20, 50, and 80 mg/cc (suspended in 0.9% saline), with a fourth group having a final fibrinogen concentration of 80 mg/cc with the addition of aprotinin (a fibrinolysis inhibitor) at 3000 units/cc. 0.25 cc of the thrombin solution was drawn up into a syringe. With a separate needle, 0.25 cc of the fibrinogen was drawn up into the same syringe for a total volume of 0.5 cc fibrin glue. Because the thrombin component of the fibrin glue is diluted to 50 units/cc, the mixture remains in liquid form for approximately 10 seconds prior to polymerizing. The liquid fibrin glue was then injected subcutaneously into the backs of nude mice (0.5 cc per injection). Each group contained four mice with four injections per mouse (16 data points per group). These groups were all euthanised at four weeks, and the remaining fibrin glue nodules were surgically harvested under the operating microscope. The mean mass and standard deviation was determined for each group.
Rate of fibrin glue degradation
This portion of the study examines the degradation of fibrin glue over time. 80 mg/cc was selected due to the results of the above experiment. Fibrin glue (0.5 cc) at 80mg/cc of fibrinogen was injected into the backs of the nude mice as above. A total of 80 injection were performed, 4 per mouse in 20 mice. Two mice were euthanised at time 0 (1 hour after implantation ) and four mice were euthanised at 2,3,4,5, and 6 weeks. The residual fibrin glue nodules were surgically harvested, yielding 16 data points per time point (and 8 data points for time 0). The mass of each fibrin glue nodule was then determined, and the mean mass and standard deviation was determined for each time point. Week 6 samples were analyzed histologically.
Phase II Fresh chondrocytes were isolated by collagenase digestion from the shoulder, hip, and knee cartilage of Yorkshire pigs. Fibrin glue was produced by mixing purified porcine fibrinogen (80 mg/cc)(Sigma Corp.) and thrombin (GenTrac) (50 units per cc in 40 mM calcium chloride). The chondrocytes were suspended in the fibrinogen prior to the addition of thrombin. The chondrocyte/polymer constructs were then injected into the subcutaneous tissue of nude mice using chondrocyte concentrations of 10, 25, and 40 million chondrocytes/cc of polymer. Injection volume was 0.4 cc. A total of 32 injections (4 per mouse) were performed for each of the three concentrations. At 6 and 12 weeks the neocartilage specimens were harvested and analyzed by histology (both H&E and safranin O staining), mass, glycosaminoglycan (GAG) content using a dimethylene blue assay, DNA content using the bisbenzimidazol fluorescent dye method., and the ratio of collagen types I and II. Control groups consisted of nude mice injected with fibrin glue alone (without chondrocytes) and a separate group injected with chondrocytes suspended in saline only (40 million cells/cc in saline, 0.4 cc injections).
Results Phase 1: Fibrin glue degradation
The mass of the fibrin glue nodules (without chondrocytes) after harvest at week four, increased as the concentration of fibrinogen increased. The addition of aprotinin to the 80 mg/cc group did result in a statistically significant increase in resultant mass (p=0.033), however the difference in mass was much greater with the change in fibrinogen concentration. The difference in the mean mass between all groups was statistically significant (p<0.05). The number of specimens is lower then the number of initial injections due to infection or anesthetic complications.
Rate of fibrin glue degradation
The mass of the fibrin glue nodules (80 mg fibrinogen/cc) decreased over a six week period from a mean mass of 0.42g at time 0 and a mass of 0.074g at week 6. The differences between the mean specimen masses of all time points were statistically significant (p<0.5) except for the difference between week 5 and 6. The difference between the mean specimen mass of week 4 and week 6, however, was statistically significant (p=0.00004).
Phase II Histological analysis of the neocartilage showed solid, homogenous cartilage when using 40 million chondrocytes/cc both at 6 and 12 weeks. The 10 and 25 million chondrocytes/cc samples showed areas of cartilage separated by areas of remnant fibrin glue. The mass of the samples ranged from 0.07-0.11g at 6 weeks and decreased only slightly by week 12. The GAG content ranged from 5.9 to 12.85% for all samples, with normal cartilage controls having 8.4 %. DNA content ranged from 0.64% to 1.5% for all samples, increasing as the initial concentration of chondrocytes increased. Normal pig cartilage had a mean DNA content of 0.285%. The fibrin glue alone samples produced no cartilage, and the chondrocytes alone produced neocartilage samples with a significantly smaller mass of 0.47 g when compared to all samples produced from chondrocytes suspended in fibrin glue (p<0.05). Chondrocyte alone samples had a mean GAG content of 10.5%, and a mean DNA content of 1.86%. Type II collagen was found to be present in all groups of tissue engineered cartilage. Type II collagen made up 95% of the total collagen in the normal cartilage sample. In the experimental groups, the percentage of type II collagen increased as the concentration of chondrocytes increased. The 10 million cells/cc group had only 18% type II collagen, while the 25 million cells/cc and the 40 million cells/cc groups had 47% and 84% type II collagen, respectively. The chondrocytes in saline control group had 35% collagen type II.
Conclusion:
This study demonstrates that fibrin glue is a suitable polymer for the formation of injectable tissue engineered cartilage in the nude mouse model. Forty million chondrocytes per cc yielded the best quality cartilage at 6 and 12 weeks when analyzed by histology, DNA, glycosaminoglycan., and collagen type II content. Because fibrin glue can be molded into a desired shape and can adhere to surrounding tissues this polymer could prove extremely useful as a means for joint resurfacing.
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